<DOC>
	<DOCNO>NCT02953743</DOCNO>
	<brief_summary>The primary purpose study assess single- multiple-dose pharmacokinetic ( PK ) profile lenvatinib Chinese participant unresectable Hepatocellular Carcinoma ( HCC ) .</brief_summary>
	<brief_title>Pharmacokinetic Study E7080/Lenvatinib Chinese Patients With Unresectable Hepatocellular Carcinoma ( HCC )</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<mesh_term>Lenvatinib</mesh_term>
	<criteria>Inclusion Criteria 1 . Participants must confirm diagnosis unresectable Hepatocellular Carcinoma ( HCC ) follow criterion : Histologically cytologically confirm diagnosis HCC Clinically confirm diagnosis HCC accord American Association Study Liver Diseases ( AASLD ) criterion , include cirrhosis etiology chronic hepatitis B C infection criterion 2 . Participants categorized stage B ( applicable transarterial chemoembolization [ TACE ] ) stage C base Barcelona Clinic Liver Cancer ( BCLC ) stag system 3 . Adequate bone marrow function , define : Absolute neutrophil count ( ANC ) ≥ 1.5 × 10^9/Liter ( L ) Hemoglobin ( Hb ) ≥ 8.5 gram per deciliter ( g/dL ) Platelet count ≥ 75 × 10^9/L 4 . Adequate liver function , define : Albumin ≥ 2.8 g/dL Bilirubin ≤ 3.0 milligram per deciliter ( mg/dL ) Aspartate aminotransferase ( AST ) , alkaline phosphatase ( ALP ) , alanine aminotransferase ( ALT ) ≤ 5 × upper limit normal ( ULN ) 5 . Adequate blood coagulation function , define international normalized ratio ( INR ) ≤ 2.3 6 . Adequate renal function define creatinine clearance &gt; 40 milliliter per min ( mL/min ) calculate per CockcroftGault formula 7 . Adequately control blood pressure ( BP ) 3 antihypertensive agent , define systolic BP ≤ 150 millimeter mercury ( mm Hg ) diastolic BP ≤ 90 mm Hg screen change antihypertensive therapy within 1 week prior registration . 8 . ChildPugh A ( score 56 ) 9 . Eastern Cooperative Oncology Group ( ECOG ) performance status ( PS ) 0 1 10 . Survival expectation 12 week longer start study drug 11 . Males female age least 18 year time inform consent . 12 . Females must lactate pregnant Screening Baseline ( document negative betahuman chorionic gonadotropin [ BetahCG ] test minimum sensitivity 25 International Unit/Liter [ IU/L ] equivalent unit betahCG ) . A separate baseline assessment require negative screening pregnancy test obtain 72 hour first dose study drug . 13 . All female consider childbearing potential unless postmenopausal ( amenorrheic least 12 consecutive month , appropriate age group without know suspected cause ) sterilize surgically ( ie , bilateral tubal ligation , total hysterectomy bilateral oophorectomy , surgery least one month dose ) . 14 . Females childbearing potential must unprotected sexual intercourse within 30 day study entry must agree use highly effective method contraception ( eg , total abstinence , intrauterine device , doublebarrier method [ condom plus diaphragm spermicide ] , contraceptive implant , oral contraceptive , vasectomized partner confirm azoospermia ) throughout entire study period 30 day study drug discontinuation . If currently abstinent , participant must agree use double barrier method describe becomes sexually active study period 30 day study drug discontinuation . Females use hormonal contraceptive must stable dose hormonal contraceptive product least 4 week dose must continue use contraceptive study 30 day study drug discontinuation . 15 . Male participant must successful vasectomy ( confirm azoospermia ) female partner must meet criterion ( ie , childbearing potential practicing highly effective contraception throughout study period 30 day study drug discontinuation ) . No sperm donation allow study period 30 day study drug discontinuation . 16 . Provide write informed consent 17 . Willing able comply aspect protocol judge Investigator . Exclusion Criteria 1 . Imaging finding HCC correspond follow : HCC ≥50 % liver occupation Clear invasion bile duct Portal vein invasion main portal branch ( Vp4 ) 2 . Participants receive lenvatinib 3 . Participants receive anticancer therapy ( include surgery , percutaneous ethanol injection , radio frequency ablation , transarterial [ chemo ] embolization , hepatic intraarterial chemotherapy , biological , immunotherapy , hormonal , investigational drug radiotherapy ) blood enhance treatment ( include blood transfusion , blood product , agent stimulate blood cell production , eg , granulocyte colonystimulating factor [ GCSF ] ) within 28 day prior registration . 4 . Participants recover toxicity result prior anticancer therapy except alopecia infertility . Recovery define &lt; Grade 2 severity per Common Terminology Criteria Adverse Events Version 4.0 ( CTCAE v4.0 ) . 5 . Significant cardiovascular impairment : history congestive heart failure great New York Heart association ( NYHA ) Class II , unstable angina , myocardial infarction stroke within 6 month first dose study drug , cardiac arrhythmia require medical treatment screen 6 . Prolongation Q wave T wave interval correct Fridericia formula ( QTcF ) interval &gt; 480 milli second ( msec ) 7 . Gastrointestinal malabsorption , condition opinion investigator might affect absorption lenvatinib 8 . Bleeding thrombotic disorder use anticoagulant require therapeutic INR monitoring , eg , warfarin similar agent . Treatment low molecular weight heparin factor X inhibitor require INR monitoring permit . Antiplatelet agent prohibit throughout study . 9 . Gastrointestinal bleeding event within 28 day prior registration 10 . Gastric esophageal varix require interventional treatment within 28 day prior randomization . Prophylaxis pharmacologic therapy ( eg , nonselective betablocker ) permit . 11 . Active hemoptysis ( bright red blood least 0.5 teaspoon ) within 28 day prior registration 12 . Active malignancy ( except HCC definitively treat melanoma insitu , basal squamous cell carcinoma skin , carcinoma insitu cervix ) within past 36 month registration . 13 . Any history current brain subdural metastases 14 . Participants &gt; 1+ proteinuria urine dipstick test undergo 24h urine collection quantitative assessment proteinuria . Participants urine protein ≥ 1 gram ( g ) /24 hour ( h ) ineligible . 15 . Surgical arterialportal venous shunt arterialvenous shunt . 16 . Any medical condition opinion investigator would preclude participation clinical study 17 . Human immunodeficiency virus ( HIV ) positive , active infection require treatment ( except hepatitis virus ) 18 . History drug alcohol dependency abuse within approximately 2 year prior registration . 19 . Any participant evaluated dynamic CT allergic reaction contrast agent CT. 20 . Major surgery within 3 week prior registration schedule surgery study 21 . Participant liver transplant . 22 . Participants whose tumor lesion ( ) bone exclude</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>E7080</keyword>
	<keyword>Lenvatinib</keyword>
	<keyword>Pharmacokinetic study</keyword>
	<keyword>Chinese participant</keyword>
	<keyword>Unresectable Hepatocellular Carcinoma</keyword>
</DOC>